The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate

Urologic Oncology

Volumn 5, Issue 3, 2000, Pages 97-103

  Kim, Jeri ^a   Palmer, J Lynn ^a   Finn, Laury ^a   Hodges, Sherie ^a   Bowes, Victoria ^b   Deftos, Leonard ^c   Murphy, Gerald ^b   Logothetis, Christopher ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Pacific NW Cancer Found/NW Hosp ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chromogranin A; Interleukin 6; Prostate specific antigen; Prostate specific membrane antigen

Indexed keywords

CHROMOGRANIN A; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL; TUMOR GROWTH;

EID: 0034607281     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(99)00047-2     Document Type: Article

References (37)

1. Kuriyama M., Wang M.C., Lee C.I.et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 41:1981;3874-3876.
2. Guinan P., Bhatti R., Ray P. An evaluation of prostate specific antigen in prostatic cancer. J Urology. 137:1987;686-689.
3. Babaian R.J., Fritsche H.A., Evans R.B. Prostate-specific antigen and prostate gland volume. correlation and clinical application J Clin Lab Anal. 4:1990;135-137.
4. Partin A.W., Carter H.B., Chan D.W.et al. Prostate specific antigen in the staging of localized prostate cancer. influence of tumor differentiation, tumor volume and benign hyperplasia J Urology. 143:1990;747-752.
5. Oesterling J.E., Chan D.W., Epstein J.I.et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urology. 139:1988;766-772.
6. Stamey T.A., Kabalin J.N., McNeal J.E.et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urology. 141:1989;1076-1083.
7. Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of prostate specific antigen in patients with prostate cancer. J Urology. 142:1989;1011-1017.
8. Lange P.H., Ercole C.J., Lightner D.J., Fraley E.E., Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urology. 141:1989;873-879.
9. Stein A., deKernion J.B., Smith R.B., Dorey F., Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urology. 147:1992;942-946.
10. Partin A.W., Pound C.R., Clemens J.Q., Epstein J.I., Walsh P.C. Serum PSA after anatomic radical prostatectomy. Urol Clin N Am. 20:1993;713-725.
11. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Tomaszewski J.E., Wein A. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer. the basis for an adjuvant therapy trial J Clin Oncol. 15:1997;1465-1469.
12. Young C.Y., Montgomery B.T., Andrews P.E., Qui S.D., Bilhartz D.L., Tindall D.J. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 51:1991;3748-3752.
13. Wood C.G., Finn L., Logothetis C.J. Prostate specific antigen (PSA) to tumor burden ratio. a prognostic variable in androgen-independent prostate cancer (AIPC) J Urology. 157:1997;297. [Abstract 1155].
14. Fossa S.D., Waehre H., Paus E. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. Brit J Cancer. 66:1992;181-184.
15. Hoosein N.M. Neuropeptides in the progression of prostate cancer. Cancer Bulletin. 45:1993;436-441.
16. Bologna M., Festuccia C., Muzi P., Biordi L., Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 63:1989;1714-1720.
17. Logothetis C., Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J Cell Biochem. 16H:1992;128-134. [suppl].
18. Hoosein N., Logothetis C.J., Chung L.W.K. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urology. 149:1993;1209-1213.
19. Hoosein N., Abdul M., McCabe R.et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol. 1:1995;246-251.
20. Diaz M., Abdul M., Hoosein N. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate. 8:1998;32-36. [suppl].
21. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6. a candidate mediator of human prostate cancer morbidity Urology. 45:1995;542-549.
22. Wright G.L., Grob B.M., Haley C.et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 48:1996;326-334.
23. Murphy G., Ragde H., Kenny G.et al. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostate cancer patients. Anticancer Res. 15:1995;1473-1480.
24. Murphy G.P., Barren R.J., Erickson S.J.et al. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer. 78:1996;809-818.
25. Hsieh J.-T., Wu H.-C., Wang Y.et al. Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer. Urol Oncol. 1:1995;67-72.
26. Soloway M.S., Hardeman S.W., Hickey D.et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 61:1988;195-202.
27. O'Connor D.T., Deftos L.J. Secretion of chromogranin A by peptide producing endocrine neoplasms. N Engl J Med. 314:1986;1145-1151.
28. O'Connor D.T., Burton D., Deftos L.J. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab. 57:1983;1084-1086.
29. Rochon Y.P., Horoszewicz J.S., Boynton A.L.et al. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate. 25:1994;219-223.
30. ® scanning in prostatic cancer patients. Prostate. 33:1997;281-285.
31. Cox D.R. Regression models and life tables. J Roy Stat Soc B Met. 34:1972;187-201.
32. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
33. Fossa S.D., Waehre H., Paus E. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. Brit J Cancer. 66:1992;181-184.
34. 89Strontium in bone metastases from hormone resistant prostate cancer. palliation effect and biochemical changes Brit J Cancer. 66:1992;177-180.
35. Cussenot O., Villette J.M., Valeri A.et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urology. 155:1996;1340-1343.
36. Logothetis, CJ, Hoosein NM, Ro J. Neuroendocrine progression. In Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, Williams & Wilkins, 1996.
37. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostate cancer patients. Anticancer Res. 7:1987;927-936.